Compare Adaptive Biotechnologies Corp (ADPT) vs F5 Inc (FFIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs F5 Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while F5 Inc trades at $418.91 (market cap $23.53B). The key difference: F5 Inc is far larger — about 7.1× Adaptive Biotechnologies Corp's market cap, and F5 Inc is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | FFIV | |
|---|---|---|
Market Cap | $3.33B | $23.53B |
Sector | Health | Technology |
52-Week High | $22.37 | $424.18 |
52-Week Low | $10.24 | $223.99 |
Enterprise Value | $3.19B | $22.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
F5 (FFIV) trades at $417.11, up 2.16% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock is technically bullish, trading above key support levels, while fundamentals show robust revenue growth to $3.09B in 2025 and a high net income margin of 21.96%. Recent strategic moves include expanding AI security offerings through acquisitions and partnerships, positioning the company in the high-growth cybersecurity sector.
The outlook remains positive given consistent earnings outperformance and strategic focus on AI security, though valuation multiples like a P/E of 34.42 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $397 price target slightly below current levels, indicating cautious optimism amid growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
